Amryt's Lojuxta license expanded eastwards

Rare and orphan disease specialist Amryt Pharma (LSE: AMYT) has announced an agreement with the Noverion Therapeutics (Nasdaq: NVLN) subsidiary Aegerion Pharmaceuticals to expand its exclusive license agreement for Lojuxta (lomitapide).

Lojuxta is an approved treatment for adults with the rare cholesterol disorder homozygous familial hypercholesterolemia (HoFH) and it is estimated that there could be up to 450 additional patients who could benefit from treatment across the countries covered by the extended agreement, which goes into Russia, the Commonwealth of Independent States and the non-European Union Balkan states.

This license expansion extends the original agreement, secured in December 2016, which covers the European Economic Area, Middle East and North Africa, Switzerland, Turkey and Israel. As part of this agreement, Amryt will formally become the marketing authorization holder for Lojuxta in Europe, which will marginally increase the level of royalties payable to Aegerion.